The pivot to a direct-to-patient model has shown the resilience of the biopharma sector. But what should the long-term response be?

For continuity in decentralized clinical trials, strong, well-communicated safeguards that give sponsors confidence in data protection are required.

The impact of the COVID-19 pandemic continues to resonate in every sector. Biopharma is no exception. Supply chains have been strained to breaking point. Clinical trials have been suspended or reconfigured. 

The pandemic is putting biopharma supply chains under incredible stress, some to an extent that’s never been experienced before. As challenging as they are, these situations can offer learning opportunities for the industry

The sheer scale and pace of change brought about by the impacts of COVID-19 are extraordinary, both for biopharma companies and their supply chain partners. The ability to respond with speed and adopt new business practices could be a key driver of success for trial sponsors. 

In response to the impact of COVID-19, organizations across all industries are re-thinking processes and establishing creative solutions. A core focus is on maintaining continuity of medical supply.

To help our customers work in the changing landscape of COVID-19, we’ve been researching how organizations have adapted their approach and how they believe practices will change moving forwards. During this webinar, we present the results.

In light of the rapid evolution of the situation in Europe and globally, due to the dynamic nature of the Covid-19 outbreak, the enablement of at home clinical trials and specialty delivery programs is now critical.

Follow the World Courier Twitter account to get hourly updates

Connect with World Courier on LinkedIn to get daily updates